LADR-7

LADR-7 is an investigational small molecule drug conjugate (SMDC) developed by LadRx Corporation (formerly CytRx Corporation). It utilizes the proprietary Linker Activated Drug Release (LADR™) technology, which is designed to allow the drug to bind to endogenous albumin in the bloodstream. This albumin-binding mechanism facilitates targeted delivery and accumulation within the tumor microenvironment, where the active payload is released in a controlled manner. The payload in LADR-7 is auristatin E, a highly potent tubulin inhibitor that disrupts microtubule assembly, leading to cell cycle arrest and apoptosis. Preclinical studies have demonstrated that LADR-7 possesses significant antitumor activity, inducing complete and partial responses in models of melanoma, ovarian cancer, non-small cell lung cancer (NSCLC), and head and neck cancers. The drug has completed substantial IND-enabling testing.

Other names

AE-Keto-Sulf07AE-Keto-Sulf-07AE-Keto-Sulf 07